Inito successfully raised $29 million in a Series B funding round led by Bertelsmann India Investments to enhance its AI-powered at-home hormone and health diagnostics platform.
Target Information
Inito is an innovative health-tech company dedicated to empowering individuals with at-home diagnostic insights specifically for reproductive health. The company’s flagship product, the Inito Fertility Monitor, is designed to help users track crucial fertility hormones by leveraging a compact device in conjunction with a smartphone application. This system provides lab-grade hormone data that assists in predicting and confirming ovulation, ultimately aiding in family planning.
By integrating advanced biomarker measurement technologies with user-friendly digital insights, Inito is committed to making personalized health tracking more accessible beyond traditional clinical environments. The company seeks to broaden the scope of at-home testing, expanding it into the wider domain of wellness diagnostics.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in India
The at-home diagnostic health sector in India is witnessing significant growth as consumers increasingly demand convenience and accessibility in healthcare. The rise of health-
Similar Deals
Accel, IDG Ventures, Endiya Partners, Pi Ventures, VH Capital, Axilor Ventures, Binny Bansal → SigTuple
2023
Life Insurance Corporation of India → Sun Pharmaceutical Industries
2026
Bertelsmann India Investments
invested in
Inito
in 2025
in a Series B deal
Disclosed details
Transaction Size: $29M